Michelle A Albert, MD, MPH


Dr. Michelle A. Albert, MD MPH is a Professor in Medicine at the University of California at San Francisco (UCSF), Admissions Dean for UCSF Medical School and Director of the CeNter for the StUdy of AdveRsiTy and CardiovascUlaR DiseasE (NURTURE Center). Dr. Albert is a graduate of Haverford College, the University of Rochester School of Medicine and Harvard School of Public Health. She completed Internal Medicine Residency and was a Chief Medical Resident at Columbia University Medical Center in New York. Dr. Albert then completed Cardiovascular Clinical and Research Fellowship at the Brigham and Women’s Hospital and Harvard Medical School, where she rose in the ranks to an Associate Professor in Medicine. She was previously the Vivian Beaumont Allen Endowed Professor/Chair and Chief of Cardiology at Howard University.

Dr. Albert maintains an active clinical practice. Her clinical expertise involves both taking care of the most critically ill heart disease patients and preventive cardiology at UCSF. As a physician-scientist-epidemiologist, Dr. Albert is engaged in cutting-edge research that innovatively seeks to incorporate “biology” with social determinants of health to transform CVD science and healthcare of global populations, i.e “the biology of adversity”. Her research has followed a bold, non-traditional path for cardiovascular disease research. A central component of her current work focuses on developing innovative implementation strategies to curb adversity related CVD risk, particularly in women and racial/ethnic minorities with a focus on health disparities and cumulative toxic stress. She is recipient of multiple research awards including NIH R01 funding, as well as funding from RWJ (Harold Amos Scholar), Kellogg and Doris Duke Foundations. Dr. Albert is a recipient of the American Heart Association (AHA) COVID-19 Rapid Track Grant. Additionally, she is one of two recipients nationally of the prestigious 2018 AHA Merit award for visionary research, and is the first woman and under-represented minority person to receive this award. Dr. Albert also received the 2020 AHA Population Science Award.

Dr. Albert is an elected member of the American Society of Clinical Investigation (ASCI). Dr. Albert is currently the 60th President of the Association of University Cardiologists (AUC). She is an Associate Editor at Atherosclerosis, Thrombosis & Vascular Biology (ATVB), serves on the Editorial Board of Circulation, where she also serves as a Guest Editor and is a Section Editor for Current Cardiovascular Risk Reports.

Albert currently serves as a member of the NHLBI Board of External Experts (BEE), 2019 ACC/AHA Cardiovascular Prevention Guidelines committee and as a standing committee member of NIH study section - Mechanisms, Emotion, Sleep & Health (MESH). She also served as a member of the National Academy of Sciences Committee on Qualification of Biomarkers and Surrogate Endpoints in Chronic Disease.

She is the President of the Association of Black Cardiologists, Inc. She is the Immediate-Past President of the American Heart Association (AHA) San Francisco Bay Area and Silicon Valley Board of Directors. Additionally, Dr. Albert has served/serves on multiple national AHA and American College of Cardiology (ACC) committees as well as currently on the Sarnoff Medical Foundation Board of Directors.

Dr. Albert enjoys mentoring trainees at all levels across the United States. She was a nominee/finalist for the competitive 2011-2012 Excellence in Mentoring Award at Harvard Medical School and the recipient of the Women in Cardiology Mentoring Award from the AHA (2016). She received the ACC Heart of Women’s Health Credo Award (2012), Woman’s Day Magazine’s Red Dress Award (2014), the 2018 Daniel D. Savage Science Award (ABC’s highest honor) and the Haverford College Alumni Award (2015) -- given to an alumnus whose “work typifies the values of the college and is of outstanding service to humanity”.
Honors and Awards
  • COVID-19 Rapid Track Science Award, American Heart Association, 2020
  • Population Science Research Award, American Heart Association, 2020
  • American Society for Clinical Investigation, American Society for Clinical Investigation, 2019
  • Merit Award, American Heart Association, 2018
  • Daniel D. Savage Science Award, Association of Black Cardiologists, 2018
  • Women in Cardiology Mentoring Award, American Heart Association, 2016
  • Elected Member, Association of University Cardiologists, 2016
  • The Haverford Award, recognizing an alumnus who uses their knowledge to the benefit of society, Haverford College, 2015
  • Featured "Editor's Choice & Scientist": MA Health Care Reform, Race/Ethnicity and CVD, Circulation Journal (June 17, 2014), 2014
  • Red Dress Award Honoree, Women's Day Magazine, 2014
  • Second Annual Heart of Women's Health CREDO Award, American College of Cardiology, 2012
  • Nesson Fellowship Award, Brigham and Women’s Hospital, Boston MA, 2010
  • J Ira and Nikki Harris Family Research Award, Brigham and Women's Hospital, Boston MA, 2006
  • Herbert W. Nickens Epidemiology Award, Association of Black Cardiologists, Inc, 2004
  • Learner Young Investigator Award,, Brigham and Women’s Hospital, Boston MA, 2003
  • Brigham and Women's Hospital/Kraft Minority Faculty Development Award, Brigham and Women’s Hospital, Boston MA, 2001
  1. Working Agenda for Black Mothers: A Position Paper From the Association of Black Cardiologists on Solutions to Improving Black Maternal Health.
  2. Dismantling Structural Discrimination in Cardiology Fellowship Recruitment.
  3. Disparities in Influenza Vaccination-Opportunity to Extend Cardiovascular Prevention to Millions of Hearts.
  4. Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized with COVID-19: Findings from the American Heart Association's COVID-19 Cardiovascular Disease Registry.
  5. The Intersection of Sexual Orientation, Gender Identity, and Race/Ethnicity on Cardiovascular Health: a Review of the Literature and Needed Research.
  6. Diversity and Inclusion: Central to ACC's Mission, Vision, and Values.
  7. Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities.
  8. Disparities in Cardiovascular Medicine: Circulation's Response.
  9. Coronary Artery Disease.
  10. Age-Stratified Sex Disparities in Care and Outcomes in Patients with ST-elevation Myocardial Infarction.
  11. At the Heart of the Matter: Unmasking and Addressing COVID-19's Toll on Diverse Populations.
  12. Racial disparities in the utilization and outcomes of transcatheter mitral valve repair: Insights from a national database.
  13. Cardiovascular Disease-Related Pregnancy Complications Are Associated with Increased Maternal Levels and Trajectories of Cardiovascular Disease Biomarkers During and After Pregnancy.
  14. Sleep debt: the impact of weekday sleep deprivation on cardiovascular health in older women.
  15. Response by Burroughs Peña et al to Letter Regarding Article, "Cumulative Psychosocial Stress and Ideal Cardiovascular Health in Older Women".
  16. Financial strain and ideal cardiovascular health in middle-aged and older women: Data from the Women's health study.
  17. Cumulative Psychosocial Stress and Ideal Cardiovascular Health in Older Women: Data by Race/Ethnicity.
  18. Ignored in Plain Sight.
  19. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.
  20. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary.
  21. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
  22. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
  23. Abstract P085: Extremes of Sleep Duration and Type II Diabetes in Older Women Participating in the Women’s Health Study.
  24. Abstract P268: Long and Short Sleep and Obesity in the Women’s Health Study.
  25. 2019 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines on the primary prevention of cardiovascular diseases.
  26. Psychosocial Stress, the Unpredictability Schema, and Cardiovascular Disease in Women.
  27. Social Networks and Health Outcomes: Importance for Racial and Socioeconomic Disparities in Cardiovascular Outcomes.
  28. RelationshipBetween Psychosocial Stressors and Atrial Fibrillation in Women >45 Years of Age.
  29. Association between neighborhood-level socioeconomic deprivation and incident hypertension: A longitudinal analysis of data from the Dallas heart study.
  30. #Me_Who: Anatomy of Scholastic, Leadership, and Social Isolation of Underrepresented Minority Women in Academic Medicine.
  31. Parity, Job Strain, and Cardiovascular Risk in the Women’s Health Study.
  32. Impact of Body Mass Index on Heart Failure by Race/Ethnicity From the Get With The Guidelines-Heart Failure (GWTG-HF) Registry.
  33. Cardiovascular Health in African Americans: A Scientific Statement From the American Heart Association.
  34. Cumulative psychological stress and cardiovascular disease risk in middle aged and older women: Rationale, design, and baseline characteristics.
  35. Psychosocial Factors and Hypertension: A Review of the Literature.
  36. Positive childhood experiences and ideal cardiovascular health in midlife: Associations and mediators.
  37. Ethnic Enclaves and Type II Diabetes: a Focus on Latino/Hispanic Americans.
  38. Temporal Trends in Care and Outcomes of Patients Receiving Fibrinolytic Therapy Compared to Primary Percutaneous Coronary Intervention: Insights From the Get With The Guidelines Coronary Artery Disease (GWTG-CAD) Registry.
  39. Neighborhood Socioeconomic Status in Relation to Serum Biomarkers in the Black Women's Health Study.
  40. Emotional and instrumental support during childhood and biological dysregulation in midlife.
  41. Racial Disparities in Child Adversity in the U.S.: Interactions With Family Immigration History and Income.
  42. Multidimensional religious involvement and tobacco smoking patterns over 9-10 years: A prospective study of middle-aged adults in the United States.
  44. Job Burnout, Job Strain (Stress), and Cardiovascular Disease: Selected Review.
  45. Childhood adversity, adult neighborhood context, and cumulative biological risk for chronic diseases in adulthood.
  46. Early results of Massachusetts healthcare reform on racial, ethnic, and socioeconomic disparities in cardiovascular care.
  47. Perceived stress is associated with incident coronary heart disease and all-cause mortality in low- but not high-income participants in the Reasons for Geographic And Racial Differences in Stroke study.
  48. Not there yet: Medicare Part D and elimination of cardiovascular medication usage sociodemographic disparities after myocardial infarction.
  49. Cumulative Psychological Stress and Cardiovascular Disease Risk: A Focused Review with Consideration of Black-White Disparities.
  50. Psychosocial stress and cigarette smoking persistence, cessation, and relapse over 9-10 years: a prospective study of middle-aged adults in the United States.
  51. Cardiac sarcoidosis: case report, workup, and review of the literature.
  52. Neighborhood disadvantage, neighborhood safety and cardiometabolic risk factors in African Americans: biosocial associations in the Jackson Heart study.
  53. Fifteen-year trends in awareness of heart disease in women: results of a 2012 American Heart Association national survey.
  54. Relationship between perceptions about neighborhood environment and prevalent obesity: data from the Dallas Heart Study.
  55. Job strain, job insecurity, and incident cardiovascular disease in the Women's Health Study: results from a 10-year prospective study.
  56. Trait anxiety and glucose metabolism in people without diabetes: vulnerabilities among black women.
  57. Psychosocial stressors and cigarette smoking among African American adults in midlife.
  58. Socioeconomic status and incident type 2 diabetes mellitus: data from the Women's Health Study.
  59. Trait anxiety and glucose metabolism in people without diabetes: vulnerabilities among black women.
  60. Biomarkers and heart disease.
  61. The VITamin D and OmegA-3 TriaL (VITAL): rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease.
  62. Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial.
  63. Invited commentary: Discrimination--an emerging target for reducing risk of cardiovascular disease?
  64. Body size misperception: a novel determinant in the obesity epidemic.
  65. The ecology of stent thrombosis: a view from a sociobiological perspective.
  66. Receipt of high-quality coronary heart disease care in the United States: all about being black or white: comment on "Racial differences in admissions to high-quality hospitals for coronary heart disease".
  67. Early life adversity and inflammation in African Americans and whites in the midlife in the United States survey.
  68. Perceptions of race/ethnic discrimination in relation to mortality among Black women: results from the Black Women's Health Study.
  69. Regarding REGARDS: Does inflammation explain racial and regional differences in cardiovascular disease risk?
  70. Candidate genetic variants in the fibrinogen, methylenetetrahydrofolate reductase, and intercellular adhesion molecule-1 genes and plasma levels of fibrinogen, homocysteine, and intercellular adhesion molecule-1 among various race/ethnic groups: data from
  71. Socioeconomic status, blood pressure progression, and incident hypertension in a prospective cohort of female health professionals.
  72. Heart failure in the urban African enclave of Soweto: a case study of contemporary epidemiological transition in the developing world.
  73. Cardiovascular risk indicators and perceived race/ethnic discrimination in the Dallas Heart Study.
  74. Race/ethnicity and inflammation: is there a link to periodontal disease?
  75. Inflammatory biomarkers, race/ethnicity and cardiovascular disease.
  76. Differential effect of soluble intercellular adhesion molecule-1 on the progression of atherosclerosis as compared to arterial thrombosis: a prospective analysis of the Women's Health Study.
  77. Relation between soluble intercellular adhesion molecule-1, homocysteine, and fibrinogen levels and race/ethnicity in women without cardiovascular disease.
  78. Chapter 9 Primary Prevention of Ischemic Heart Disease.
  79. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events.
  80. C-reactive protein as a risk predictor: do race/ethnicity and gender make a difference?
  81. The effect of statin therapy on lipoprotein associated phospholipase A2 levels.
  82. Surgical treatment of a large left-main coronary artery aneurysm.
  83. Perspective on selected issues in cardiovascular disease research with a focus on black Americans.
  84. C-reactive protein levels among women of various ethnic groups living in the United States (from the Women's Health Study).
  85. Effect of physical activity on serum C-reactive protein.
  86. Inflammatory biomarkers in African Americans: a potential link to accelerated atherosclerosis.
  87. Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial.
  88. Plasma concentration of C-reactive protein and the calculated Framingham Coronary Heart Disease Risk Score.
  89. Alcohol consumption and plasma concentration of C-reactive protein.
  90. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study.
  91. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design.
  92. Plasma levels of cystatin-C and mannose binding protein are not associated with risk of developing systemic atherosclerosis.
  93. The role of C-reactive protein in cardiovascular disease risk.
  94. The role of C-reactive protein in cardiovascular disease risk.